| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| Carolyn Cross |
156,314,029 |
£17,663,485 |
| Nicolas Loebel |
3,538,991 |
£399,906 |
| Junaid Bajwa |
1,193,697 |
£134,888 |
| Jean Duvall |
1,163,529 |
£131,479 |
| Jean Charest |
353,356 |
£39,929 |
| Carolyn Cross |
119,258,222 |
£13,476,179 |
| M&G Plc |
67,254,901 |
£7,599,804 |
| hInsight-NX, LLC |
42,272,654 |
£4,776,810 |
| Robert Cross |
37,772,652 |
£4,268,310 |
| Albemarle Life Sciences Fund |
15,105,882 |
£1,706,965 |
| CRUX Asset Management |
9,298,090 |
£1,050,684 |
| Chelverton Asset Management |
7,957,311 |
£899,176 |
| 16:35 |
24,995 @ 11.30p |
| 16:35 |
24,995 @ 11.30p |
| 15:33 |
1,000 @ 11.39p |
| 08:00 |
400 @ 11.50p |
| 08:00 |
2,207 @ 11.50p |
| Chair |
Jean Charest |
| CEO |
Carolyn Cross |
Top of Page
You are here:
research